Description

CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue investigated within peptide and endocrine research. Studies explore its interaction with growth hormone signalling pathways and its relationship with IGF-1 activity. Research into CJC-1295 focuses on understanding GHRH-mediated pathways and the mechanisms involved in growth hormone regulation. The compound has attracted interest across research areas involving endocrine signalling, peptide activity, and growth hormone-related biological processes. CJC-1295 is supplied in a 10mg × 10 vial presentation, with the listed price ranging from $688 to $899. It provides researchers with a defined peptide material for controlled laboratory investigations into growth hormone signalling and related endocrine pathways.